Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293344 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1PLGLMNATHRB | |
| SCHEMBL7159116 | 1.00 | MEN1 (0.43) | MEN1ALDH1A1PLGLMNATHRB | |
| SCHEMBL934384 | 0.92 | CES2 (0.44) | MEN1KMT2ASLC6A5GNAI3GNAO1 | |
| SCHEMBL2770560 | 0.86 | GNAI3 (0.42) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL9119248 | 0.81 | CES2 (0.52) | — | |
| SCHEMBL4958852 | 0.81 | CES2 (0.52) | — | |
| SCHEMBL8917791 | 0.81 | CES2 (0.52) | — | |
| SCHEMBL2304845 | 0.81 | CES2 (0.52) | — | |
| SCHEMBL5802863 | 0.81 | CES2 (0.52) | — | |
| SCHEMBL9868874 | 0.81 | CES2 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110191867-A1 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | GLYKOS FINLAND OY (FI) | 2011-08-04 | — | — | US | disclosed |
| EP-2296688-A2 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | Glykos Finland Oy (FI) | 2011-03-23 | — | — | EP | disclosed |
| US-20100081629-A1 | LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| US-20100074920-A1 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | GLYKOS FINLAND OY (FI) | 2010-03-25 | — | — | US | disclosed |
| EP-2121769-A1 | LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009133249-A1 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | GLYKOS FINLAND OY (FI) | 2009-11-05 | — | — | WO | disclosed |
| EP-2091960-A2 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | Glykos Finland Oy (FI) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009053535-A2 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | GLYKOS FINLAND OY (FI) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008113919-A1 | LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008049974-A2 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | GLYKOS FINLAND OY (FI) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074920-A1 | PEPTIDE VACCINE FOR INFLUENZA VIRUS | SIGLEC7, SIGLEC9, NEU3 | MEN1 2385/4885ALDH1A1 4602/4885PLG 3788/4885 |
| US-20100081629-A1 | LOW MOLECULAR WEIGHT HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR MAKING SAME AND USE THEREOF | BTD, CD44, HLCS | MEN1 2181/4885ALDH1A1 1755/4885PLG 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.